Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 1
R&D Momentum
18/100
Pipeline Velocity
0/100
Trial Completion Rate
89/100
Pipeline Concentration
100/100
Pipeline Freshness
50/100
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Sodium Bicarbonate — OMEPRAZOLE AND SODIUM BICARBONATE
Application ANDA204923
Sodium Bicarbonate — OMEPRAZOLE AND SODIUM BICARBONATE
Application ANDA205545
Hytrin — TEZRULY
Application NDA218139 (NDA)
Sodium Bicarbonate — PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE
Application ANDA204559
Sodium Bicarbonate — PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE
Application ANDA204559
Sodium Bicarbonate — OMEPRAZOLE AND SODIUM BICARBONATE
Application ANDA217784
Sodium Bicarbonate — SODIUM BICARBONATE
Application ANDA216042
Sodium Bicarbonate — OMEPRAZOLE AND SODIUM BICARBONATE
Application ANDA201361
Sodium Bicarbonate — OMEPRAZOLE AND SODIUM BICARBONATE
Application ANDA219161
Sodium Bicarbonate — ZEGERID OTC
Application NDA022281
Sodium Bicarbonate — SODIUM BICARBONATE
Application ANDA206688
Sodium Bicarbonate — SODIUM BICARBONATE
Application ANDA219701
Sodium Bicarbonate — SODIUM BICARBONATE
Application NDA218524
Alka-Seltzer — SODIUM BICARBONATE
Application NDA218524 (NDA)
Sodium Bicarbonate — SODIUM BICARBONATE
Application NDA220790 (NDA)
Sodium Bicarbonate — SODIUM BICARBONATE
Application NDA220790 (NDA)
Sodium Bicarbonate — SODIUM BICARBONATE
Application NDA220790
Alka-Seltzer — SODIUM BICARBONATE
Application NDA220790 (NDA)
Sodium Bicarbonate — SODIUM BICARBONATE
Application ANDA219089
Sodium Bicarbonate — SODIUM BICARBONATE
Application ANDA217523
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)